Bicycle Therapeutics will present data describing the mechanism of action of BT1718, Bicycle’s lead molecule, which is being developed to target cancers of high unmet need. The data will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Philadelphia, Pennsylvania from October 26 – 30, 2017.
Details for the poster presentation, which will be given by Gavin Bennett, Ph.D., Bicycle’s Head of Preclinical Development, are as follows:
Title: The mechanism of action of BT1718, a novel small-molecule drug conjugate for the treatment of solid tumours expressing MT1-MMP
Session: PO.B20 – Therapeutic Agents: Other Topics
Poster #: B135
Date & Time: Sunday, October 29, 2017, 12:30 – 4:00 p.m. ET